{"url_path":"/sec/mnpr/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 ** **Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-021350-index.html","accession_number":"0001437749-26-021350","cik":"0001645469","ticker":"MNPR","issuer_name":"Monopar Therapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-021350-index.html","primary_entity_key":"0001645469","primary_entity_name":"Monopar Therapeutics"},"word_count":527,"has_tables":true,"body_markdown":"**Item 5.07** **Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 22, 2026, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,698,778 shares of the Company’s common stock were entitled to vote as of April 27, 2026, the record date for the Annual Meeting, of which 5,760,392 shares were represented in person or by proxy at the Annual Meeting. At the Annual Meeting, the stockholders of the Company voted on the following proposals:\n\n \n\n(1) the election of six directors to the Company’s Board of Directors to serve until the Company’s next annual meeting of stockholders or until their respective successors are duly elected and qualified; \n\n \n\n(2) the approval of the compensation of the Company’s named executive offers (“NEOs”) on an advisory, non-binding basis;\n\n \n\n(3) the approval of the Company’s 2026 Stock Incentive Plan; and\n\n \n\n(4) the ratification of the selection of BPM LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\n \n\n2\n\n \n\n***Proposal 1***-***Election of Directors***\n\n \n\nAt the Annual Meeting, the voting results with respect to the proposal for the election of directors, included in the Company’s Proxy Statement on Schedule 14A for the Annual Meeting, were as follows:\n\n \n\n**Director**\n\n**For**\n\n**Withheld**\n\n**Broker Non-Votes**\n\nChristopher M. Starr, Ph.D.\n\n4,203,485\n\n757,652\n\n799,255\n\nChandler D. Robinson, MD MBA MSc\n\n4,447,108\n\n514,029\n\n799,255\n\nRaymond W. Anderson, MBA MS\n\n4,671,362\n\n289,775\n\n799,255\n\nKim R. Tsuchimoto\n\n4,325,379\n\n635,758\n\n799,255\n\nLavina Talukdar, CFA\n\n4,897,733\n\n63,404\n\n799,255\n\nNicole Sweeny\n\n4,911,758\n\n49,379\n\n799,255\n\n \n\nAccordingly, each of the foregoing persons was elected as a director at the Annual Meeting.\n\n \n\n***Proposal 2***-***Approval of the Compensation of the Company***’***s Named Executive Officers on an Advisory, Non-Binding Basis***\n\n \n\nThe voting results with respect to the proposal to approve the compensation of the Company’s NEOs on an advisory, non-binding basis, were as follows:\n\n \n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker Non-Votes**\n\n4,355,628\n\n604,858\n\n651\n\n799,255\n\n \n\nAccordingly, the Company’s stockholders approved the compensation of the Company’s NEOs on an advisory, non-binding basis.\n\n \n\n***Proposal 3*** –***Approval of the Company***’***s 2026 Stock Incentive Plan***\n\n \n\nThe voting results with respect to the proposal to approve the Company’s 2026 Stock Incentive Plan were as follows:\n\n \n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker Non-Votes**\n\n4,444,209\n\n516,570\n\n358\n\n799,255\n\n \n\nAccordingly, the Company’s stockholders approved the Company’s 2026 Stock Incentive Plan.\n\n \n\n***Proposal 4*** -***Ratification of the Company***’***s Selection of Independent Registered Public Accounting Firm*** \n\n \n\nThe voting results with respect to the proposal to ratify the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026, were as follows:\n\n \n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker Non-Votes**\n\n5,759,198\n\n998\n\n196\n\nN/A\n\n \n\nAccordingly, the Company’s stockholders ratified the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\n \n\nNo other matters were submitted to a vote of stockholders at the Annual Meeting.\n\n \n\n3\n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n**Monopar Therapeutics Inc.**\n\n \n\n \n\n \n\n \n\n \n\nDate: June 23, 2026\n\nBy:\n\n/s/ Quan Vu\n\n \n\n \n\nName:\n\nQuan Vu\n\n \n\n \n\nTitle:\n\nChief Financial Officer"}